Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$265.8M
Burn Rate (Qtr)
$12.6M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q1 '22
Drug Pipeline
Click on drug name or indication to see upcoming trial info, prior data, and more general information.
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
EWTX
Company Profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Recent Posts
See what the community is saying - click to see full post.